This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About REMICADE® (infliximab)

Updated on 04/10/2019

IMMUNOLOGY

REMICADE has over 20 years of experience of treating patients with immune-mediated diseases in the field of Rheumatology, Gastroenterology and Dermatology1

What is REMICADE?

REMICADE is a monoclonal antibody; it is a TNFα (Tumour Necrosis Factor–alpha) inhibitor that is indicated for the treatment of a range of immune-mediated inflammatory disorders.1

REMICADE is a prescription-only product. It is presented as powder (100 mg/vial) to be reconstituted with water, diluted with saline and thereafter administered via intravenous infusion.1

About REMICADE

*From launch to August 2018

Further information about REMICADE

Gastroenterology

View more information for Gastroenterology HCP’s

Visit page

Rheumatology

View more information for Rheumatology HCP’s

Visit page

Pharmacy

View more information for pharmacists

Visit page

Patient website

Visit the REMICADE patient website

Visit myREMICADE.co.uk

References

  1. REMICADE Summary of Product Characteristics.
  2. European Medicines Agency. REMICADE: Scientific discussion. December 2005. Available from https://www.ema.europa.eu/en/documents/scientific-discussion/remicade-epar-scientific-discussion_en.pdf.
  3. European Medicines Agency. Humira: Procedural steps taken and scientific information after the authorisation. December 2018. Available from https://www.ema.europa.eu/en/documents/procedural-steps-after/humira-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf.
  4. European Medicines Agency. REMICADE: Steps taken after granting the marketing authorisation. December 2005. Available from https://www.ema.europa.eu/en/documents/steps-after-cutoff/remicade-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf.
  5. European Medicines Agency. REMICADE: Procedural steps taken and scientific information after the authorisation. March 2019. Available from https://www.ema.europa.eu/en/documents/procedural-steps-after/remicade-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf.
  6. MSD data on file [PSUR, GB-MAB-00040 April 2019].

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-MAB-00063 | Date of Preparation: October 2019